No Support for BTK Inhibitor in Phase 3 MS Trial No Support for BTK Inhibitor in Phase 3 MS Trial

The phase 3 MS trial of the BTK inhibitor evobrutinib was not superior to teriflunomide for any endpoint.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery Source Type: news